Ty-jour t1 - 纤维化肺血管渗透率JF - 欧洲呼吸杂志Jo - Eur Respir J Do - 10.1183 / 13993003.00100-2019 SP - 1900100 Au - Probst，Clemens K. Au - Montesi，悉尼B. Au - Medoff，BenjaminD. Au - Shea，Barry S. Au - Knipe，Rachel S. Y1 - 2020/01/01 Ur - //www.qdcxjkg.com/content/early/2020/04/01/13993003.00100-2019.AbstractN2 - 特发性肺纤维化（IPF）被认为是由异常组织修复过程产生响应慢性或重复性肺损伤。损伤的起源和性质以及其细胞和分子靶标可能是异质的，这使得精确的疾病预临床典型建模使治疗性造成挑战。正在进行努力识别纤维发生中的中央途径，这可能允许靶向异常修复过程，无论初始损伤刺激。长期以来已经研究了呼吸困难的内皮渗透性和血管泄漏，以便在急性肺损伤和修复中作用。证据表明，这些过程对纤维化肺病的发病性具有重要性。在非纤溶肺病中，内皮渗透性增加，但它在细菌肺炎和急性呼吸窘迫综合征（ARDS）等条件下以自动限制方式解决。然而，在逐步纤维疾病如IPF，渗透性似乎持续存在，也可能预测死亡率。在这一假设的审查中，我们总结了有关内皮渗透性在IPF中的作用的可用数据，并专注于肺炎炎症和纤维化期间持续的内皮高温易率的有害后果。 We propose that persistent permeability and vascular leak in the lung have the potential to establish and amplify the pro-fibrotic environment. Therapeutic interventions aimed at recognising and “plugging” the leak may therefore be of significant benefit for preventing the transition from lung injury to fibrosis and should be areas for future research.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Probst has nothing to disclose.Conflict of interest: Dr. Montesi reports other from United Therapeutics Corporation, other from Promedior, outside the submitted work.Conflict of interest: Dr. Medoff has nothing to disclose.Conflict of interest: Dr. Shea reports personal fees from Genentech, personal fees from Boehringer Ingelheim, outside the submitted work.Conflict of interest: Dr. Knipe has nothing to disclose. ER -